CPMV (Mosaic ImmunoEngineering) LT-Debt-to-Total-Asset : 34.35 (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is Mosaic ImmunoEngineering LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Mosaic ImmunoEngineering's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 34.35.

Mosaic ImmunoEngineering's long-term debt to total assets ratio increased from Sep. 2023 (4.54) to Sep. 2024 (34.35). It may suggest that Mosaic ImmunoEngineering is progressively becoming more dependent on debt to grow their business.

Mosaic ImmunoEngineering LT-Debt-to-Total-Asset Historical Data

The historical data trend for Mosaic ImmunoEngineering's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mosaic ImmunoEngineering LT-Debt-to-Total-Asset Chart

Mosaic ImmunoEngineering Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

2.73

4.71

7.32

Mosaic ImmunoEngineering Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															4.54	7.32	16.92	113.00	34.35

Mosaic ImmunoEngineering LT-Debt-to-Total-Asset Calculation

Mosaic ImmunoEngineering's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1.318	/	0.18
	=

Mosaic ImmunoEngineering's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	1.374	/	0.04
	=

Mosaic ImmunoEngineering (OTCPK:CPMV) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Mosaic ImmunoEngineering LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Mosaic ImmunoEngineering's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Mosaic ImmunoEngineering Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mosaic ImmunoEngineering Inc (OTCPK:CPMV) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

9114 Adams Avenue, Suite 202, Huntington Beach, CA, USA, 92646

Website

https://www.mosaicie.com

Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. It has a single operating segment for the purposes of assessing performance and making operating decisions.

Executives

Robert Baffi	director	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Case Western Reserve University	10 percent owner	10900 EUCLID AVENUE, CLEVELAND OH 44106
Steven W King	director, officer: President and CEO
Paul J Lytle	director, officer: EVP, Chief Financial Officer
Robert L Garnick	director	C/O PATRIOT SCIENTIFIC, 2038 CORTE DEL NOGAL, SUITE 141, CARLSBAD CA 92011
Nicole Franziska Steinmetz	director, officer: Chief Scientific Officer	871 WILBUR AVENUE, SAN DIEGO CA 92019
Dharmesh Mistry	director	315 PEMBROKE COURT, SAN RAMON CA 94582
Carlton M Johnson	director
Donald E Schrock	director	C/O INTEGRATED DEVICE TECHNOLOGY, INC., 6024 SILVER CREEK VALLEY ROAD, SAN JOSE CA 95138
Paul R Bibeau	officer: VP, Business Development	MICROSEMI CORP, 2381 MORSE AVE, IRVINE CA 92614
Frederick C Goerner	officer: Chief Executive Officer	MICROSEMI CORPORATION, ONE ENTERPRISE, ALISO VIEJO CA 92656
Clifford L Flowers	officer: Chief Financial Officer	C/O BAKBONE SOFTWARE, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO CA 92121
Harry L Tredennick	director	6183 PASEO DEL NORTE #180, CARLSBAD CA 92011
Thomas J Sweeney	officer: CFO
Helmut Jr Falk	director